Novadaq to hold fiscal 2007 year-end and fourth quarter results conference call and webcast

Wednesday, March 19, 2008 General News
Email Print This Page Comment bookmark
Font : A-A+

TORONTO, March 18 /PRNewswire-FirstCall/ - Novadaq(R) Technologies Inc.(TSX: NDQ), a developer of real-time medical imaging systems and image guidedtherapies for the operating room, will host a conference call and live webcaston Tuesday, March 25, 2008 at 4:30 p.m. E.T. to discuss the financial resultsfor the fourth quarter and full year ended December 31, 2007.

To access the conference call by telephone, dial 416-644-3417 or1-800-732-6179. Please connect approximately ten minutes prior to thebeginning of the call to ensure participation. The conference call will bearchived for replay until April 1, 2008 at midnight. To access the archivedconference call, dial 416-640-1917 or 1-877-289-8525 and enter the reservationnumber 21266249 followed by the number sign.

A live audio webcast of the conference call will be available Please connect at least ten minutes prior to the conferencecall to ensure adequate time for any software download that may be required tojoin the webcast. The webcast will be archived at the above website for 365days.

About Novadaq Technologies

Novadaq Technologies Inc. (TSX: NDQ) develops and commercializes medicalimaging systems and real-time image guided therapies for use in the operatingroom. Novadaq's proprietary ICG imaging systems can be used to visualize bloodvessels, nerves and the lymphatic system during a variety of surgicalprocedures. Novadaq's SPY(R) Imaging System, commercially available worldwide,enables cardiac surgeons to visually assess coronary vasculature and bypassgraft functionality during the course of heart bypass surgery. The SPY Systemis expandable to include upgrade kits for use during other surgeries such asother cardiovascular, plastic, reconstructive and organ transplant surgeryallowing surgeons to evaluate blood flow and tissue and organ perfusion. Inaddition, SPY is ideal for use during urological procedures enabling surgeonsto visualize vessels, tumors, the lymphatic system and potentially nervebundles. Novadaq's OPTTX(R) System is aimed at the diagnosis, evaluation andtreatment of wet Age-related Macular Degeneration (AMD) by using the same coreimaging technology that is used in the SPY Imaging System. Novadaq also offersthe FDA approved PINPOINT(TM) endoscopic system for visualizing native tissuefluorescence which allows surgeons to differentiate between healthy andcancerous tissue in the lung during thoracic surgery. Novadaq is also theexclusive United States distributor of PLC Medical's CO2 HEART LASER(TM)System for TMR (Trans-Myocardial Revascularization). For more information,please visit the company's website at

Forward looking Statements

Certain statements included in this press release may be consideredforward-looking. Such statements involve known and unknown risks,uncertainties and other factors that may cause actual results, performance orachievements to be materially different from those implied by such statements,and therefore these statements should not be read as guarantees of futureperformance or results. All forward-looking statements are based on Novadaq'scurrent beliefs as well as assumptions made by and information currentlyavailable to Novadaq and relate to, among other things, anticipated financialperformance, business prospects, strategies, regulatory developments, marketacceptance and future commitments. Readers are cautioned not to place unduereliance on these forward-looking statements, which speak only as of the dateof this press release. Due to risks and uncertainties, including the risks anduncertainties identified by Novadaq in its public securities filings; actualevents may differ materially from current expectations. Novadaq disclaims anyintention or obligation to update or revise any forward-looking statements,whether as a result of new information, future events or otherwise.

SOURCE Novadaq T

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store